Literature DB >> 20714111

Heavy-chain complementarity-determining regions determine conformation selectivity of anti-aβ antibodies.

Dag Sehlin1, Marie Hedlund, Anna Lord, Hillevi Englund, Pär Gellerfors, Staffan Paulie, Lars Lannfelt, Frida Ekholm Pettersson.   

Abstract

BACKGROUND/AIMS: Amyloid-β (Aβ) protofibrils are neurotoxic soluble intermediates in the Aβ aggregation process eventually forming senile plaques in Alzheimer's disease. This Aβ species is a potential biomarker for Alzheimer's disease and also a promising target for immunotherapy. In this study, we investigated the characteristics of conformation-dependent Aβ antibodies specific for Aβ protofibrils.
METHODS: Mice were immunized with Aβ protofibrils to generate hybridomas producing Aβ-specific monoclonal antibodies. Binding of antibodies to different Aβ conformations was investigated with inhibition ELISA. The antibodies' complementarity-determining region (CDR) sequences were determined and compared.
RESULTS: A majority of the antibodies were of the IgM class, all selectively binding to aggregated Aβ. Two IgG antibodies were generated: one with selective affinity for Aβ protofibrils and the other bound Aβ in all conformations. A high degree of similarity between the heavy-chain CDRs of the conformation-dependent antibodies was found, and all high-affinity Aβ antibodies displayed a high degree of sequence similarity in the light-chain CDRs.
CONCLUSION: Sequence similarity in the heavy-chain CDRs is associated with conformation selectivity of the antibodies, while sequence similarity in the light-chain CDRs correlates with the affinity for Aβ.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20714111     DOI: 10.1159/000316530

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  9 in total

1.  Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation.

Authors:  Dag Sehlin; Hillevi Englund; Barbro Simu; Mikael Karlsson; Martin Ingelsson; Fredrik Nikolajeff; Lars Lannfelt; Frida Ekholm Pettersson
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

2.  Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.

Authors:  Oskar Hansson; Sara Hall; Annika Ohrfelt; Henrik Zetterberg; Kaj Blennow; Lennart Minthon; Katarina Nägga; Elisabet Londos; Shiji Varghese; Nour K Majbour; Abdulmonem Al-Hayani; Omar Ma El-Agnaf
Journal:  Alzheimers Res Ther       Date:  2014-05-07       Impact factor: 6.982

3.  Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease.

Authors:  Dag Sehlin; Xiaotian T Fang; Linda Cato; Gunnar Antoni; Lars Lannfelt; Stina Syvänen
Journal:  Nat Commun       Date:  2016-02-19       Impact factor: 14.919

4.  Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor.

Authors:  Greta Hultqvist; Stina Syvänen; Xiaotian T Fang; Lars Lannfelt; Dag Sehlin
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

5.  The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death.

Authors:  Sofia Söllvander; Elisabeth Nikitidou; Linn Gallasch; Marlena Zyśk; Linda Söderberg; Dag Sehlin; Lars Lannfelt; Anna Erlandsson
Journal:  J Neuroinflammation       Date:  2018-03-28       Impact factor: 8.322

Review 6.  Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease.

Authors:  Kenjiro Ono; Mayumi Tsuji
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

7.  A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Authors:  Chad J Swanson; Yong Zhang; Shobha Dhadda; Jinping Wang; June Kaplow; Robert Y K Lai; Lars Lannfelt; Heather Bradley; Martin Rabe; Akihiko Koyama; Larisa Reyderman; Donald A Berry; Scott Berry; Robert Gordon; Lynn D Kramer; Jeffrey L Cummings
Journal:  Alzheimers Res Ther       Date:  2021-04-17       Impact factor: 8.823

8.  Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta.

Authors:  Fadi Rofo; Jos Buijs; Ronny Falk; Ken Honek; Lars Lannfelt; Anna M Lilja; Nicole G Metzendorf; Tobias Gustavsson; Dag Sehlin; Linda Söderberg; Greta Hultqvist
Journal:  Transl Neurodegener       Date:  2021-09-28       Impact factor: 8.014

9.  Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

Authors:  Veronika Logovinsky; Andrew Satlin; Robert Lai; Chad Swanson; June Kaplow; Gunilla Osswald; Hans Basun; Lars Lannfelt
Journal:  Alzheimers Res Ther       Date:  2016-04-06       Impact factor: 8.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.